The Beta Cell Responsiveness to Glucose-dependent Insulinotropic Polypeptide (GIP) With and Without Sulfonylurea in Patients With Type 2 Diabetes

• Status: Completed
• Trial end date: 2007-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The investigators hypothesize that the impaired insulinotropic effect of the incretin hormone GIP may be due to inadequate sensitization and ATP induced closure of beta cell K-ATP channels. By closing the channels through the use of sulfonylurea (SU) we hope to restore the insulinotropic effect of GIP.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Hospital, Gentofte, Copenhagen
• Treatments: Gastric Inhibitory Polypeptide

Criteria

Inclusion Criteria:

• Type 2 diabetes mellitus diagnosed according to WHO criteria

• Diet and/or metformin treatment

• HbA1c > 7,0% for metformin treated patients

• HbA1c > 7,5% for diet treated patients

• Age: 18 years or older

• 25 > BMI > 40 kg/m2

• Signed informed consent

• Sufficient birth control in case of child bearing capacity

Exclusion Criteria:

• Proliferative retinopathy

• Diabetic nephropathy with s-creatinine > 130 microM and/or macroalbuminuria

• Liver disease (ALAT > 2 x normal value)

• CAD (NYHA group III or IV)

• Positive screening for islet-cell and/or GAD-65 autoantibodies

• Type 1 diabetes i first degree relatives

• Gastrointestinal surgery with intestinal resection

• Anemia

• Pregnancy and/or breastfeeding